• decreased number of B220+ cells peripherally (J:35769)

• reduced numbers of mature IgM-IgD+ B cells (J:35769)

• deficiency of CD5+ B cells in the peritoneum for B cells expressing both the mutant and the wild-type allele (J:35769)

• decreased number of B220+ cells peripherally (J:35769)

• reduced numbers of mature IgM-IgD+ B cells (J:35769)

• deficiency of CD5+ B cells in the peritoneum for B cells expressing both the mutant and the wild-type allele (J:35769)

• B cell development is completely blocked (J:94768)

• dramatic reductions of immature IgM+IgD- B cells in the bone marrow (J:94768)

• dramatic reductions of mature IgM+IgD+ B cells in the bone marrow (J:94768)

• IgG3 severely reduced (J:94768)

• severely reduced (J:94768)

• increased frequency of pre-B cell lymphomas (J:94768)

• B cell development is completely blocked (J:94768)

• dramatic reductions of immature IgM+IgD- B cells in the bone marrow (J:94768)

• dramatic reductions of mature IgM+IgD+ B cells in the bone marrow (J:94768)

• B cell development is completely blocked (J:94768)

• dramatic reductions of immature IgM+IgD- B cells in the bone marrow (J:94768)

• B cell development is partially restored, by about 4-7 fold (J:94768)

• some differentiation into mature B cells occurs (J:94768)

• recirculationg B cell population in the bone marrow is improved (J:94768)

• IgG3 levels remain severely reduced (J:94768)

• improved or restored (J:94768)

• tumor suppressor function is restored (J:94768)

• B cell development is partially restored, by about 4-7 fold (J:94768)

• some differentiation into mature B cells occurs (J:94768)

• recirculationg B cell population in the bone marrow is improved (J:94768)

• B cell development is partially restored, by about 4-7 fold (J:94768)

• some differentiation into mature B cells occurs (J:94768)

• recirculationg B cell population in the bone marrow is improved (J:94768)

• calcium signaling of splenic B cells is restored (J:94768)

• B cell apoptosis is reduced compared to similar mice lacking the transgene (J:120989)

• differentiation is partially restored (J:120989)

• restored B220+ cell numbers peripherally (J:120989)

• deficiency of CD5+ B cells in the peritoneum remains (J:120989)

• decreased lambda light chain usage (J:120989)

• differentiation is partially restored (J:120989)

• restored B220+ cell numbers peripherally (J:120989)

• deficiency of CD5+ B cells in the peritoneum remains (J:120989)

• B cell apoptosis is reduced compared to similar mice lacking the transgene (J:120989)

• differentiation is partially restored (J:120989)

• development through to large pre-B cell stage is normal (J:35769)

• transition from pre-B to immature B cell is impaired (J:35769)

• decreased number of B220+ cells peripherally (J:35769)

• thymocyte and T cell numbers are unaffected (J:35769)

• reduced IgM⁺IgD^- to about 70% of normal numbers at 5 weeks of age (J:35769)

• mature IgM^lowIgD^high are nearly absent (J:35769)

• deficiency of CD5+ B cells in the peritoneum (J:35769)

• significantly reduced calcium signaling in splenic B cells (J:94768)

• decreased lambda light chain usage (J:120989)

• IgG3 reduced 20% at 5 weeks of age (J:35769)

• reduced 50% at 5 weeks of age (J:35769)

• no response to T cell independent type II antigens (J:120989)

• development through to large pre-B cell stage is normal (J:35769)

• transition from pre-B to immature B cell is impaired (J:35769)

• decreased number of B220+ cells peripherally (J:35769)

• thymocyte and T cell numbers are unaffected (J:35769)

• reduced IgM⁺IgD^- to about 70% of normal numbers at 5 weeks of age (J:35769)

• mature IgM^lowIgD^high are nearly absent (J:35769)

• deficiency of CD5+ B cells in the peritoneum (J:35769)

• development through to large pre-B cell stage is normal (J:35769)

• transition from pre-B to immature B cell is impaired (J:35769)

• reduced IgM⁺IgD^- to about 70% of normal numbers at 5 weeks of age (J:35769)